FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks-February 2024-www.financetom.com

FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks

Mar 8, 2024 11:07 AM

March 8 (Reuters) - The U.S. FDA has approved Novo

Nordisk's Wegovy for use in lowering the risk of

stroke and heart attack in overweight or obese adults, the

Danish drugmaker said on Friday.

Previous page： Visa reduces charges levied on debit card transactions, says report Next page： TCS Board Meet: What to expect

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Visa reduces charges levied on debit card transactions, says report

Jun 15, 2018

India’s largest payment card network Visa has slashed down charges levied on debit card transactions, reported The Economic Times. Share...

TCS Board Meet: What to expect

Jun 15, 2018

India’s largest software exporter previously said that it would pay out up to 100 percent of its free cash flows to shareholders.

TCS hits lifetime high on share buyback plan; board approves share buyback of up to Rs 16,000 crore

Jun 15, 2018

The Tata Consultancy Services' board approved the share buyback proposal of shares worth up to Rs 16,000 crore.

Expect agrochemicals business to grow at 15-20% this year, says Meghmani Organics

Jun 15, 2018

Meghmani Organics, a maker of pigment and pesticide products, is in focus as normal monsoon will likely improve the prospects...